apomorphine hydrochloride
Onapgo
Pharmaceutical company: Supernus Pharmaceuticals
NEW AVAILABLE FORM
Solution for infusion: 98 mg/20 mL (4.9 mg/mL) in single-dose cartridges
NEW INDICATION & DOSAGE
Motor fluctuations in patients with advanced Parkinson disease
Adults: Initially, 1 mg/hr subcut infusion for up to 16 hours per day. Titrate, as needed, no more than once per day in 0.5 mg/hr to 1 mg/hr increments. Maximum, 6 mg/hr while awake during the day, up to 16 hours. May give bolus dose when starting the infusion in the morning, when restarting the infusion after a 1-hour or longer break, or to supplement continuous infusion to manage acute, uncontrolled "off" symptoms. Titrate bolus dose to clinical response and tolerance in increments of 0.5 mg or 1 mg. Maximum bolus, 2 mg. Give no more than 3 bolus doses per day with at least 3 hours between doses. Consider increasing the continuous infusion rate if 3 bolus doses/day are routinely required. Total maximum daily dosage, including bolus doses, is 98 mg.
Adjust-a-dose: In patients with mild to moderate kidney impairment, don't exceed 1 mg for initial bolus dose.
Released: April 2025
Nursing Drug Handbook
© 2025 Wolters Kluwer N.V., its subsidiaries and/or its licensors. All rights reserved.
brentuximab vedotin
Adcetris
Pharmaceutical company: Pfizer, Inc.
NEW INDICATION & DOSAGE
Relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy in patients who are not eligible for autologous hematopoietic stem cell transplantation or chimeric antigen receptor T-cell therapy, in combination with lenalidomide and rituximab
Adults: 1.2-mg/kg IV infusion every 3 weeks or until disease progression or unacceptable toxicity occurs. Maximum dose, 120 mg. Give with granulocyte colony-stimulating factor beginning cycle 1.
Adjust-a-dose: In patients with normal total bilirubin and AST greater than the upper limit of normal (ULN), or total bilirubin more than 1 to 1.5 x ULN and any AST, reduce dosage to 0.9 mg/kg every 3 weeks. Maximum dose, 90 mg. Avoid use in patients with total bilirubin more than 1.5 x ULN.
Released: April 2025
Nursing Drug Handbook
© 2025 Wolters Kluwer N.V., its subsidiaries and/or its licensors. All rights reserved.
ranibizumab
Susvimo
Pharmaceutical company: Genentech
NEW INDICATION & DOSAGE
Diabetic macular edema in patients who have previously responded to at least two intravitreal injections of a VEGF inhibitor (Susvimo)
Adults: 2 mg (0.02 mL of 100 mg/mL solution) continuous delivery by ocular implant with refills every 24 weeks.
Adjust-a-dose: May give a supplemental intravitreal injection to affected eye, with ocular implant in place, if needed.
Released: April 2025
Nursing Drug Handbook
© 2025 Wolters Kluwer N.V., its subsidiaries and/or its licensors. All rights reserved.
semaglutide
Ozempic
Pharmaceutical company: Novo Nordisk
NEW INDICATION & DOSAGE
Reduce risk of sustained estimated GFR decline, kidney failure, and cardiovascular death in patients with type 2 diabetes and chronic kidney disease (Ozempic only)
Adults: Initially, 0.25 mg subcut once weekly for 4 weeks; then increase to 0.5 mg once weekly. After 4 weeks, increase to maintenance dose of 1 mg once weekly.
Released: April 2025
Nursing Drug Handbook
© 2025 Wolters Kluwer N.V., its subsidiaries and/or its licensors. All rights reserved.